5 AstraZeneca employees detained in China over data irregularities & unapproved drug import.

Chinese authorities have detained five employees of AstraZeneca amid investigations into potential data irregularities and the import of an unapproved liver cancer drug. The inquiry, led by Shenzhen police, targets alleged illegal activities related to patient data collection. This situation poses risks to AstraZeneca's operations in China, which contribute 12% to its revenues. The company has not yet issued a statement regarding the detentions.

September 05, 2024
30 Articles